5-MeO-DMT Dose: What Human Studies Actually Used
There is no medical 5-MeO-DMT dose. Published studies gave it as an inhaled vapour at 2 to 18 mg or a nasal powder at 1 to 12 mg, always with screening and monitoring.
What 5-MeO-DMT doses did human studies use?
There is no medical 5-MeO-DMT dose. Published studies gave it as an inhaled vapour at 2 to 18 mg or a nasal powder at 1 to 12 mg; toad-secretion studies did not measure the dose. Every study screened and monitored participants.
There is no medical “5-MeO-DMT dose”. In published human studies it was inhaled as a vapour at 2 to 18 mg, given as a nasal powder at 1 to 12 mg, or smoked as dried toad secretion whose 5-MeO-DMT content nobody measured, always with screening and monitoring.
This page sets out what those studies actually gave people, how long the effects lasted, what they found and what went wrong. It is not dosing advice. 5-MeO-DMT is a Schedule I controlled substance in the United States, and the milligram figures below come from research settings with medical cover.
What doses of 5-MeO-DMT did research studies use?
The controlled trials used single-digit to low double-digit milligrams: inhaled GH001 at 6, 12 and 18 mg, and intranasal BPL-003 at 1 to 12 mg. The toad and naturalistic studies did not weigh individual doses. Each row links to the study on PubMed.
| Study | How it was given | Dose given | Who took part | What it found | The main limitation |
|---|---|---|---|---|---|
| Reckweg, healthy volunteers, 2021 | Inhaled (vaporised GH001) | 2, 6, 12 or 18 mg once; or 6 then 12 then 18 mg, 3 hours apart | 22 healthy volunteers | All 4 people on the step-up schedule had a peak experience, against 4 of 18 on a single dose | 4 to 6 people per dose; no placebo |
| Reckweg, depression, 2023 | Inhaled (vaporised GH001) | 12 or 18 mg once; or up to 6, 12 and 18 mg, 3 hours apart | 16 with treatment-resistant depression | 7 of 8 on the step-up schedule were in remission at day 7 | Open-label, no control group, very small |
| Cubala, phase 2b, 2026 | Inhaled (vaporised GH001) | Up to 6, 12 and 18 mg, 1 hour apart, vs placebo | 81 with treatment-resistant depression | 57.5% in remission at day 8 vs 0% on placebo | Participants could likely tell what they got; 7-day blinded period |
| Rucker, BPL-003, 2024 | Intranasal powder (benzoate salt) | 1 to 12 mg, single dose | 44 healthy volunteers (31 on drug) | Effects rose with dose; 60% had a 'complete mystical experience' at 10 and 12 mg | 4 to 5 people per dose |
| Uthaug, toad secretion, 2019 | Smoked dried toad secretion | Not weighed; authors estimate about 7.5 to 36 mg of 5-MeO-DMT | 42 ceremony participants | Lower depression, anxiety and stress at 4 weeks | No control group; doses unknown; many lost to follow-up |
| Davis, naturalistic group, 2019 | Inhaled synthetic (group-tested 98 to 100% pure) | Not reported per person | 362 survey respondents | 80% of those with depression said it improved | Self-report, looking back; one group |

Why do the trials step the dose up?
The GH001 trials give a low dose first and add a higher one only if the person has not had a full “peak” experience and the earlier dose was safe. According to the 2021 healthy-volunteer study, all four people on this step-up schedule reached a peak experience, against four of 18 on a single fixed dose. In the 2026 phase 2b trial, the steps were 6, 12 and 18 mg, one hour apart, and most people did not need the top step: 22.5% stopped after 6 mg, 52.5% after 12 mg, and only 25% took all three. That is the detail we have not seen any other page state: in practice, the trial dose was set by each person’s response, not by a fixed number.
Why the same milligram figure can mean different amounts
The studies used different products and routes, so their milligram numbers are not directly comparable. GH001 is a liquid formulation vaporised and inhaled in one breath; BPL-003 is a benzoate salt blown into the nose as a dry powder; neither paper says whether its figure is the salt or the pure compound. Usona’s injected trial used a succinate salt. Toad secretion is not pure 5-MeO-DMT at all: samples tested in the 2019 study were about 25 to 30% 5-MeO-DMT, alongside bufotenine, a separate Schedule I compound. Street material adds a further unknown, because its purity is rarely tested.

How long does 5-MeO-DMT last?
Inhaled 5-MeO-DMT is one of the shortest psychedelic experiences studied: about 9 to 18 minutes in the GH001 trials. The nasal powder lasted longer, about 45 to 90 minutes. In the 2021 study the drug was barely measurable in the blood three hours later. The only human half-life we could verify is for the nasal form, 15 to 27 minutes. That short window is why researchers see it as a treatment that could fit into a single clinic visit.
How long 5-MeO-DMT's effects lasted, by how it was taken
What did the depression trials find?
According to the first randomised trial, published in JAMA Psychiatry in 2026, depression scores dropped sharply within a week, and the earlier open-label study pointed the same way. In the phase 2b trial of 81 people with treatment-resistant depression, depression scores (MADRS) fell 15.5 points more on GH001 than on placebo by day 8, and 57.5% were in remission against none on placebo. Of the 23 who were in remission at day 8, 20 were still in remission at six months, though most had been treated again along the way (median six weeks to the first retreatment). The limits are real: the blinded phase lasted only a week, the effects are hard to disguise, so participants likely knew what they had received, and the trial was funded by the drug’s maker. Read alongside the open-label 2023 study, in which 7 of 8 people on the step-up schedule were in remission at day 7, it is a strong early signal that still needs a longer trial.
Inhaled GH001 “resulted in significant improvements in depression symptoms relative to placebo and was well tolerated.”
What risks did the studies record?
No serious adverse events were reported in the controlled trials. The most common side effect was nausea, and short-lived rises in blood pressure were recorded. In the phase 2b trial 72.5% of people on GH001 had a side effect (7.3% on placebo), none severe; nausea affected 42.5%, and excess salivation and tingling 20% each. In the nasal-powder study five of 44 people had a brief rise in systolic blood pressure above 160 mmHg. The trials screened people first and excluded anyone with psychosis or bipolar disorder, and people on antidepressants were tapered off before dosing.
The most serious documented harms involved 5-MeO-DMT taken with an MAO inhibitor. Brush et al. (2004) describe severe poisoning in a teenager who combined harmaline with 5-MeO-DMT (Brush et al., 2004), and Sklerov et al. (2005) document a death after a preparation combining harmala alkaloids with the drug (Sklerov et al., 2005). Harmala alkaloids are the MAO-inhibiting part of ayahuasca, so it must never be combined with ayahuasca or any MAOI medicine.
Is 5-MeO-DMT legal in the United States?
No. It has been a Schedule I controlled substance since January 2011, under a DEA rule published in December 2010 (75 FR 79296; 21 CFR 1308.11(d)(15)). The trials above ran under research licences. Outside them, people seeking a supervised experience usually travel to retreats abroad, where screening and medical cover vary widely. Our guide to 5-MeO-DMT retreats covers what to check before booking, and our 5-MeO-DMT therapy page explains how supervised programmes work.
Is 5-MeO-DMT the same as DMT?
No. They are different compounds, and a dose of one is not interchangeable with a dose of the other. Inhaled 5-MeO-DMT trials used 6 to 18 mg; DMT studies used larger amounts by different routes. For the DMT figures, see what doses human DMT studies used; for what the experience itself is like, see our 5-MeO-DMT experience guide. If you are weighing 5-MeO-DMT against ibogaine or other options, talk to an advocate: we visit every clinic we recommend, and the call is confidential.
Related on this site: 5-MeO-DMT therapy · 5-MeO-DMT retreats · DMT doses in research · the 5-MeO-DMT experience · ibogaine vs 5-MeO-DMT
What do people ask about 5-MeO-DMT doses in research?
How many milligrams of 5-MeO-DMT did studies use?
Inhaled GH001 trials used 2, 6, 12 and 18 mg, usually stepped up from 6 mg. The nasal powder BPL-003 was tested at 1 to 12 mg. Products and routes differ, so the figures are not strictly comparable.
How long does a 5-MeO-DMT experience last?
Inhaled, about 9 to 18 minutes in trials. The nasal powder lasted about 45 to 90 minutes.
What dose was used in the 5-MeO-DMT depression trial?
The 2026 phase 2b trial of GH001 gave up to three inhaled doses, 6, 12 and 18 mg, one hour apart, stopping once a person had a full experience. Only 25% needed all three.
Is 5-MeO-DMT dangerous?
Controlled trials reported no serious adverse events; nausea and brief blood pressure rises were common. The most serious documented harms came from combining it with MAO inhibitors such as harmala alkaloids.
Sources and further reading
- Front Pharmacol (2021): Reckweg et al., phase 1 dose-ranging study of vaporised 5-MeO-DMT (GH001) — n=22
- Front Psychiatry (2023): Reckweg et al., phase 1/2 GH001 in treatment-resistant depression — open-label, n=16
- JAMA Psychiatry (2026): Cubala et al., GH001 vs placebo in treatment-resistant depression — randomised, n=81
- J Psychopharmacol (2024): Rucker et al., phase 1 intranasal BPL-003 — placebo-controlled, n=44
- Psychopharmacology (2019): Uthaug et al., single inhalation of toad secretion — naturalistic, n=42
Talk to an advocate.
A confidential conversation about your situation and the options actually worth considering — from people who have been through it themselves.
